© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Bausch + Lomb Corporation (BLCO) stock declined over -1.14%, trading at $16.49 on NYSE, down from the previous close of $16.68. The stock opened at $16.30, fluctuating between $16.28 and $16.89 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Apr 02, 2026 | 16.34 | 16.89 | 16.28 | 16.49 | 350.43K |
| Apr 01, 2026 | 16.07 | 16.76 | 15.89 | 16.68 | 753.04K |
| Mar 31, 2026 | 15.51 | 16.06 | 15.41 | 15.90 | 706.62K |
| Mar 30, 2026 | 15.39 | 15.51 | 15.14 | 15.26 | 574.05K |
| Mar 27, 2026 | 15.74 | 15.78 | 15.37 | 15.37 | 313.05K |
| Mar 25, 2026 | 15.93 | 16.15 | 15.76 | 16.02 | 371.76K |
| Mar 24, 2026 | 15.69 | 15.83 | 15.49 | 15.71 | 488.85K |
| Mar 23, 2026 | 16.09 | 16.40 | 15.82 | 15.84 | 416.5K |
| Mar 20, 2026 | 16.23 | 16.25 | 15.58 | 15.72 | 374K |
| Mar 19, 2026 | 15.82 | 16.29 | 15.79 | 16.17 | 621.8K |
| Mar 18, 2026 | 16.56 | 16.80 | 15.98 | 16.02 | 409.6K |
| Mar 17, 2026 | 16.55 | 16.77 | 16.44 | 16.71 | 528.54K |
| Mar 16, 2026 | 16.32 | 16.60 | 16.32 | 16.49 | 470.95K |
| Mar 13, 2026 | 16.57 | 16.75 | 16.16 | 16.20 | 349.66K |
| Mar 12, 2026 | 17.26 | 17.28 | 16.56 | 16.58 | 571.81K |
| Mar 11, 2026 | 17.28 | 17.68 | 17.20 | 17.50 | 296.45K |
| Mar 10, 2026 | 17.10 | 17.48 | 16.89 | 17.12 | 164.57K |
| Mar 09, 2026 | 16.79 | 17.23 | 16.70 | 17.22 | 435.06K |
| Mar 06, 2026 | 17.20 | 17.34 | 16.87 | 17.06 | 357.91K |
| Mar 03, 2026 | 17.89 | 18.22 | 17.48 | 17.98 | 428.87K |
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
| Employees | 13500 |
| Beta | 0.58 |
| Sales or Revenue | $4.15B |
| 5Y Sales Change% | 0.13% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Medical - Instruments & Supplies |